Efficacy and metabolic outcomes of switching from an INSTI-based triple-drug regimen to dolutegravir/lamivudine in treatment-experienced HIV-1-infected patients: a 48-week real-world study. [PDF]
Ann MedZhang W, Li Q, Deng C, Yuan J.
europepmc +1 more source
HIV low-level viraemia: considerations for prevention and treatment in an era of highly effective and durable antiretroviral therapy regimens. [PDF]
J Int AIDS SocVojnov L +8 more
europepmc +1 more source
Synthesis of 1-substituted-4-[4-(1H-indol-3-yl)butyl]piperazines
ARKIVOC, 2013 Linas Labanauskas +5 more
doaj +1 more source
Exploring the pharmacokinetic mechanisms that affect bictegravir exposure during pregnancy. [PDF]
J Antimicrob Chemothervan der Wekken-Pas L +10 more
europepmc +1 more source
Four-year complete remission with reduced-dose PARP inhibitor in advanced-stage epithelial ovarian cancer harboring a BRCA1 mutation: a case report of a chemotherapy-intolerant patient with idiopathic thrombocytopenic purpura. [PDF]
J Ovarian ResLu P +5 more
europepmc +1 more source
KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status. [PDF]
Cancer Treat Res CommunXu Z +7 more
europepmc +1 more source
Explainable Artificial Intelligence (xAI) for 5-HT<sub>2A</sub> Receptor Binding Affinity of New Psychoactive Substances. [PDF]
MoleculesSchöning V +5 more
europepmc +1 more source
Ecopipam, a Dopamine D1 Receptor Antagonist: Pharmacokinetics, Mass Balance, and Metabolism in Healthy Volunteers. [PDF]
Clin Transl SciSchmith VD +7 more
europepmc +1 more source
Adverse Drug Reactions Related to Isoniazid Preventive Therapy Among Persons Living With HIV on Dolutegravir-Based Regimens in Uganda Between July 2019 and March 2020. [PDF]
J Acquir Immune Defic SyndrNalugga EA +14 more
europepmc +1 more source